Mood Disorder R&D, Lacking Innovation, Turns to Psychedelics
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward... Read More
Your Edge In Biotech.
About Stacy Lawrence
Stacy Lawrence has been writing and editing about the business of emerging technologies for almost 20 years. Most recently, she was editor-in-chief of FierceBiotech, where she covered biotech and medtech. She’s also held spots as the biopharma business bureau editor with Elsevier and the finance columnist with biotechnology industry publication BioCentury. Stacy has contributed to publications including Nature Biotechnology, San Francisco Business Times, New Scientist, MIT Technology Review, Business 2.0, and Wired.
Latest Contributions
Antibiotic Resistance Looms Large in Pandemic; CRISPR Phages Show Promise
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward... Read More
Race and Life Sciences: Where is the Healing?
When I started to go to the J.P. Morgan Healthcare Conference, it was still known as H&Q after boutique bank Hambrecht & Quist that had... Read More
Next-gen Synthetic Biology Pushes Further Into Drug Discovery, mRNA and DNA on the Desktop
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward... Read More
DNA Sequencing Startups Aim to Reduce Cost, Increase Meaning in the Data
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward... Read More
Complexity in Motion: Multi-Omics Tools Unravel Path From Genotype to Phenotype
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward... Read More
Biopharma Gets Serious, In a Hurry, About Virtual Clinical Trials
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward... Read More
Beyond CAR-T: New Engineered Immune Cell Types Head to the Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward... Read More